Anixa Biosciences Receives US Patent Notice of Allowance for Potential Ovarian Cancer Vaccine

MT Newswires Live03-24

Anixa Biosciences (ANIX) said Monday that it received a notice of allowance from the US Patent and Trademark Office for its patent application covering its potential ovarian cancer vaccine.

The patent application includes claims related to methods for eliciting an immune response targeting the anti-Mullerian hormone receptor, type II, or AMHR2, a target for ovarian cancer prevention and treatment, Anixa said.

The allowed claims include methods of administering an immunogenic composition consisting of a nucleic acid encoding the AMHR2 polypeptide, the company said.

Anixa said its ovarian cancer vaccine is being developed in collaboration with the Cleveland Clinic and the National Cancer Institute.

Shares of Anixa were up more than 3% in recent premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2521723668?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-24 20:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2521723668","market":"hk","top_or_hot":-1,"title":"Anixa Biosciences Receives US Patent Notice of Allowance for Potential Ovarian Cancer Vaccine","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ANIX\">Anixa Biosciences</a> (ANIX) said Monday that it received a notice of allowance from the US Patent and Trademark Office for its patent application covering its potential ovarian cancer vaccine.</p><p>The patent application includes claims related to methods for eliciting an immune response targeting the anti-Mullerian hormone receptor, type II, or AMHR2, a target for ovarian cancer prevention and treatment, Anixa said.</p><p>The allowed claims include methods of administering an immunogenic composition consisting of a nucleic acid encoding the AMHR2 polypeptide, the company said.</p><p>Anixa said its ovarian cancer vaccine is being developed in collaboration with the Cleveland Clinic and the National Cancer Institute.</p><p>Shares of Anixa were up more than 3% in recent premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Anixa Biosciences Receives US Patent Notice of Allowance for Potential Ovarian Cancer Vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnixa Biosciences Receives US Patent Notice of Allowance for Potential Ovarian Cancer Vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-24 20:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ANIX\">Anixa Biosciences</a> (ANIX) said Monday that it received a notice of allowance from the US Patent and Trademark Office for its patent application covering its potential ovarian cancer vaccine.</p><p>The patent application includes claims related to methods for eliciting an immune response targeting the anti-Mullerian hormone receptor, type II, or AMHR2, a target for ovarian cancer prevention and treatment, Anixa said.</p><p>The allowed claims include methods of administering an immunogenic composition consisting of a nucleic acid encoding the AMHR2 polypeptide, the company said.</p><p>Anixa said its ovarian cancer vaccine is being developed in collaboration with the Cleveland Clinic and the National Cancer Institute.</p><p>Shares of Anixa were up more than 3% in recent premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ANIX","symbol_name":"Anixa Biosciences","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2521723668","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2521723668","pubTimestamp":1742820007,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Anixa Biosciences  said Monday that it received a notice of allowance from the US Patent and Trademark Office for its patent application covering its potential ovarian cancer vaccine.The patent application includes claims related to methods for eliciting an immune response targeting the anti-Mullerian hormone receptor, type II, or AMHR2, a target for ovarian cancer prevention and treatment, Anixa said.The allowed claims include methods of administering an immunogenic composition consisting of a nucleic acid encoding the AMHR2 polypeptide, the company said.Anixa said its ovarian cancer vaccine is being developed in collaboration with the Cleveland Clinic and the National Cancer Institute.Shares of Anixa were up more than 3% in recent premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ANIX":"Anixa Biosciences","BK4139":"生物科技"},"translate_title":"Anixa Biosciences收到潜在卵巢癌疫苗的美国专利许可通知","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANIX":1},"content_text":"Anixa Biosciences (ANIX) said Monday that it received a notice of allowance from the US Patent and Trademark Office for its patent application covering its potential ovarian cancer vaccine.The patent application includes claims related to methods for eliciting an immune response targeting the anti-Mullerian hormone receptor, type II, or AMHR2, a target for ovarian cancer prevention and treatment, Anixa said.The allowed claims include methods of administering an immunogenic composition consisting of a nucleic acid encoding the AMHR2 polypeptide, the company said.Anixa said its ovarian cancer vaccine is being developed in collaboration with the Cleveland Clinic and the National Cancer Institute.Shares of Anixa were up more than 3% in recent premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2521723668","isCrawlerRequest":true}